Cancer Treatment News and Research

RSS

Men treated by self-referring urologists more likely to undergo unnecessary IMRT

A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy (IMRT) for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine (NEJM) for its October 24, 2013 issue.

25 Oct 2013

Use of IMRT for prostate cancer doubles when self-referral's financial incentives involved

A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine for its October 24, 2013 issue.

25 Oct 2013

Rice University research reveals 3-way genetic switch for cancer metastasis

Cancer researchers from Rice University have deciphered the operating principles of a genetic switch that cancer cells use to decide when to metastasize and invade other parts of the body. The study found that the on-off switch's dynamics also allows a third choice that lies somewhere between "on" and "off." The extra setting both explains previously confusing experimental results and opens the door to new avenues of cancer treatment.

25 Oct 2013

"One-two punch" disables tumors' defenses

An aggressive form of breast cancer known as "triple negative" is very difficult to treat: Chemotherapy can shrink such tumors for a while, but in many patients they grow back and gain resistance to the original drugs.

25 Oct 2013

Thomas Jefferson University’s interactive program discusses pros and cons of prostate cancer treatment

When the pros and cons of prostate cancer treatment are spelled out using an online interactive program developed by Thomas Jefferson University researchers, more patients choose active surveillance over therapy, according to research being presented Wednesday (October 23rd) at the Society for Medical Decision Making annual meeting in Baltimore, Maryland.

24 Oct 2013

Patient assistance programs help breast cancer patients to learn more about adjuvant therapy

Patient assistance programs can help breast cancer patients meet a variety of needs that can interfere with getting recommended adjuvant therapies such as radiation, chemotherapy, and hormonal treatments, according to a study published recently in the online edition of the Journal of Oncology Practice.

24 Oct 2013

Imugene Acquiring Biolife, As Lead Pipeline Candidate Nears Phase II

...

23 Oct 2013

Scientist receives NIH New Innovator Award to design innovative approaches for cancer treatment

Derek Taylor, PhD, a member of the Case Western Reserve School of Medicine, has been awarded the prestigious New Innovator Award by the National Institutes of Health (NIH).

22 Oct 2013

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO), have participated in an international phase III study, published in The New England Journal of Medicine.

18 Oct 2013

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs, researchers at Oregon State University report in a new study.

18 Oct 2013

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.

17 Oct 2013

Detroit Lions, Josephine Ford Cancer Institute to raise $15M for cancer research in metro Detroit

The Detroit Lions and Josephine Ford Cancer Institute, Michigan's largest provider of adult cancer care, have created a unique partnership with the goal to raise $15 million during the next three years for cancer research in metro Detroit.

16 Oct 2013

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience, Inc., a leading global drug discovery and development service company, today announces that it has entered into a collaboration with Xstrahl Ltd, a leading designer and manufacturer of X-Ray solutions for radiation biology research.

From Xstrahl 15 Oct 2013

Promising new type of cancer treatment to benefit more patients

More patients than ever stand to benefit from a promising new type of cancer treatment, after scientists compiled a library of molecules that can prime patients’ immune systems to fight a range of cancers including leukaemia, myeloma, lung cancer and skin cancer.

15 Oct 2013

DIM compound derived from cruciferous vegetable protects rodents from radiation doses

Georgetown University Medical Center researchers say a compound derived from cruciferous vegetable such as cabbage, cauliflower and broccoli protected rats and mice from lethal doses of radiation.

15 Oct 2013

Scientists discover genetic mutation associated with low-risk bladder cancer

An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer.

13 Oct 2013

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

...

11 Oct 2013

Reducing risk factors like hypertension might lower risk of heart disease for childhood survivors

For childhood cancer survivors, risk factors associated with lifestyle, particularly hypertension, dramatically increase the likelihood of developing serious heart problems as adults, according to a national study led by St. Jude Children's Research Hospital. The findings appear in the current issue of the Journal of Clinical Oncology.

11 Oct 2013

Gemcitabine drug improves survival rates in patients with pancreatic cancer

Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in the October 9 issue of JAMA.

9 Oct 2013

Mitsubishi Electric to provide proton beam therapy system to Hakuhokai Group healthcare organization

Mitsubishi Electric Corporation announced today that it will provide its innovative proton beam therapy system for cancer treatment to the Hakuhokai Group healthcare organization led by Chairman Motohisa Kojo in Osaka, Japan. The system will be installed at the Hakuhokai Group Osaka Proton Therapy Clinic scheduled to open in April 2016.

9 Oct 2013

Cancer Treatment News and Research

Men treated by self-referring urologists more likely to undergo unnecessary IMRT

Use of IMRT for prostate cancer doubles when self-referral's financial incentives involved

Rice University research reveals 3-way genetic switch for cancer metastasis

"One-two punch" disables tumors' defenses

Thomas Jefferson University’s interactive program discusses pros and cons of prostate cancer treatment

Patient assistance programs help breast cancer patients to learn more about adjuvant therapy

Imugene Acquiring Biolife, As Lead Pipeline Candidate Nears Phase II

Scientist receives NIH New Innovator Award to design innovative approaches for cancer treatment

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Detroit Lions, Josephine Ford Cancer Institute to raise $15M for cancer research in metro Detroit

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Promising new type of cancer treatment to benefit more patients

DIM compound derived from cruciferous vegetable protects rodents from radiation doses

Scientists discover genetic mutation associated with low-risk bladder cancer

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

Reducing risk factors like hypertension might lower risk of heart disease for childhood survivors

Gemcitabine drug improves survival rates in patients with pancreatic cancer

Mitsubishi Electric to provide proton beam therapy system to Hakuhokai Group healthcare organization

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News